{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:05:47Z","timestamp":1791896747572,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004385","name":"Universiteit Gent","doi-asserted-by":"publisher","award":["2021.01773"],"award-info":[{"award-number":["2021.01773"]}],"id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/01253"],"award-info":[{"award-number":["PI22\/01253"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-31859\/2017"],"award-info":[{"award-number":["POCI-01-0145-FEDER-31859\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["PTDC\/MED-ONC\/4165\/2021"],"award-info":[{"award-number":["PTDC\/MED-ONC\/4165\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["DL 57\/2016\/CP1360\/CT0009"],"award-info":[{"award-number":["DL 57\/2016\/CP1360\/CT0009"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001271","name":"Chartered Institute of Management Accountants","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"publisher","award":["CEECIND\/00697\/2018"],"award-info":[{"award-number":["CEECIND\/00697\/2018"]}],"id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"publisher","award":["RYC2022-038084-I"],"award-info":[{"award-number":["RYC2022-038084-I"]}],"id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["2021.01773"],"award-info":[{"award-number":["2021.01773"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PI22\/01253"],"award-info":[{"award-number":["PI22\/01253"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA21135"],"award-info":[{"award-number":["CA21135"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jconrel.2025.01.042","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:23:40Z","timestamp":1737692620000},"page":"621-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Chitosan\/\u03b3-PGA nanoparticles and IFN-\u03b3 immunotherapy: A dual approach for triple-negative breast cancer treatment"],"prefix":"10.1016","volume":"379","author":[{"given":"Fl\u00e1via","family":"Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Laranjeiro","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Leite Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Serre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c2ngela Margarida","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cavadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio Adolfo","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Vermaelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"G\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Madeira","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"De Wever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jconrel.2025.01.042_bb0005","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1073\/pnas.80.12.3782","article-title":"Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma","volume":"80","author":"Pace","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2025.01.042_bb0010","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.01.042_bb0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-gamma: teammate or opponent in the tumour microenvironment?","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41467-023-44391-9","article-title":"FOXP3(+) regulatory T cell perturbation mediated by the IFNgamma-STAT1-IFITM3 feedback loop is essential for anti-tumor immunity","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2025.01.042_bb0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ijc.24401","article-title":"Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages","volume":"125","author":"Duluc","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.01.042_bb0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.actbio.2015.05.022","article-title":"An interferon-gamma-delivery system based on chitosan\/poly(gamma-glutamic acid) polyelectrolyte complexes modulates macrophage-derived stimulation of cancer cell invasion in vitro","volume":"23","author":"Cardoso","year":"2015","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0035","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood.V97.1.192","article-title":"Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis","volume":"97","author":"Street","year":"2001","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jconrel.2025.01.042_bb0040","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1073\/pnas.93.15.7673","article-title":"Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma","volume":"93","author":"Bromberg","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.jconrel.2025.01.042_bb0045","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.4049\/jimmunol.166.4.2276","article-title":"IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma","volume":"166","author":"Beatty","year":"2001","journal-title":"J. Immunol."},{"issue":"7652","key":"10.1016\/j.jconrel.2025.01.042_bb0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature22311","article-title":"Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression","volume":"545","author":"Kammertoens","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jconrel.2025.01.042_bb0055","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-gamma signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2025.01.042_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05069.x","article-title":"Clinical use of interferon-gamma","volume":"1182","author":"Miller","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000247","article-title":"Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy","volume":"8","author":"Schroeder","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0070","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jps.10007","article-title":"Interferon-gamma therapy: evaluation of routes of administration and delivery systems","volume":"91","author":"Younes","year":"2002","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0075","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1038\/s41467-023-40028-z","article-title":"A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors","volume":"14","author":"Zibelman","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.01.042_bb0080","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3389\/fimmu.2017.01383","article-title":"Toll-like receptor ligands and interferon-gamma synergize for induction of antitumor M1 macrophages","volume":"8","author":"Muller","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0085","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-023-00364-1","article-title":"Applications and clinical trial landscape using toll-like receptor agonists to reduce the toll of cancer","volume":"7","author":"Rolfo","year":"2023","journal-title":"NPJ Precis Oncol."},{"issue":"9","key":"10.1016\/j.jconrel.2025.01.042_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002408","article-title":"Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity","volume":"9","author":"Anfray","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0095","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1476-4598-13-60","article-title":"Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy","volume":"13","author":"Chang","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.01.042_bb0100","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"9","key":"10.1016\/j.jconrel.2025.01.042_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092364","article-title":"Bringing macrophages to the frontline against cancer: current immunotherapies targeting macrophages","volume":"10","author":"Reis-Sobreiro","year":"2021","journal-title":"Cells"},{"issue":"15","key":"10.1016\/j.jconrel.2025.01.042_bb0110","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1074\/jbc.M507788200","article-title":"IRF-8\/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways","volume":"281","author":"Zhao","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2025.01.042_bb0115","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1501139","article-title":"IFN-\u03b3 prevents adenosine receptor (A2bR) upregulation to sustain the macrophage activation response","volume":"195","author":"Cohen","year":"2015","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.01.042_bb0120","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.immuni.2006.02.014","article-title":"IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB\/AP-1 proteins","volume":"24","author":"Hu","year":"2006","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jconrel.2025.01.042_bb0125","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.immuni.2013.08.009","article-title":"Synergistic activation of inflammatory cytokine genes by interferon-gamma-induced chromatin remodeling and toll-like receptor signaling","volume":"39","author":"Qiao","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1128\/IAI.67.1.206-212.1999","article-title":"Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1","volume":"67","author":"Held","year":"1999","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0135","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1038\/s41467-019-11147-3","article-title":"IFN-gamma selectively suppresses a subset of TLR4-activated genes and enhancers to potentiate macrophage activation","volume":"10","author":"Kang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.01.042_bb0140","doi-asserted-by":"crossref","first-page":"100252","DOI":"10.1016\/j.mtadv.2022.100252","article-title":"Harnessing chitosan and poly-(\u03b3-glutamic acid)-based biomaterials towards cancer immunotherapy","volume":"15","author":"Lima","year":"2022","journal-title":"Mater. Today Adv."},{"issue":"9","key":"10.1016\/j.jconrel.2025.01.042_bb0145","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1039\/D0BM01984D","article-title":"Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of in vitro, in vivo and clinical studies","volume":"9","author":"Lima","year":"2021","journal-title":"Biomater. Sci."},{"issue":"22","key":"10.1016\/j.jconrel.2025.01.042_bb0150","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1016\/j.biomaterials.2011.03.052","article-title":"The induction of innate and adaptive immunity by biodegradable poly(gamma-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway","volume":"32","author":"Uto","year":"2011","journal-title":"Biomaterials"},{"issue":"41","key":"10.1016\/j.jconrel.2025.01.042_bb0155","doi-asserted-by":"crossref","first-page":"35447","DOI":"10.1074\/jbc.M111.274936","article-title":"Chitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis","volume":"286","author":"Bueter","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.01.042_bb0160","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.actbio.2017.09.016","article-title":"Pro-inflammatory chitosan\/poly(gamma-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity","volume":"63","author":"Castro","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2025.01.042_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120218","article-title":"Chitosan\/gamma-PGA nanoparticles-based immunotherapy as adjuvant to radiotherapy in breast cancer","volume":"257","author":"Castro","year":"2020","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.jconrel.2025.01.042_bb0170","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s10856-012-4639-x","article-title":"Biosynthesis of highly pure poly-gamma-glutamic acid for biomedical applications","volume":"23","author":"Pereira","year":"2012","journal-title":"J. Mater. Sci. Mater. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0175","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jconrel.2025.01.042_bb0180","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.jconrel.2025.01.042_bb0185","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/2159-8290.CD-18-1454","article-title":"Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer","volume":"9","author":"Sceneay","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yexmp.2006.06.007","article-title":"Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors","volume":"82","author":"DuPre","year":"2007","journal-title":"Exp. Mol. Pathol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.01.042_bb0195","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2025.01.042_bb0200","article-title":"Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients, Ther Adv","volume":"10","author":"Karachaliou","year":"2018","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.01.042_bb0205","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","article-title":"Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity","volume":"180","author":"Lugade","year":"2008","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.01.042_bb0210","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.ymthe.2020.12.037","article-title":"Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway","volume":"29","author":"Jia","year":"2021","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2025.01.042_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201901706","article-title":"Enhanced prevention of breast tumor metastasis by nanoparticle-delivered vitamin E in combination with interferon-gamma","volume":"9","author":"Wu","year":"2020","journal-title":"Adv. Healthc. Mater."},{"issue":"3","key":"10.1016\/j.jconrel.2025.01.042_bb0220","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jlb.43.3.232","article-title":"Tumor cell killing and cytostasis by C3H\/HeJ macrophages activated in vitro by lipid A-associated protein and interferon gamma","volume":"43","author":"Chapes","year":"1988","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.042_bb0225","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.it.2005.11.005","article-title":"Triggering TLR signaling in vaccination","volume":"27","author":"van Duin","year":"2006","journal-title":"Trends Immunol."},{"issue":"12","key":"10.1016\/j.jconrel.2025.01.042_bb0230","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.4049\/jimmunol.175.12.8200","article-title":"CD11b+\/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells","volume":"175","author":"Song","year":"2005","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.01.042_bb0235","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166847","article-title":"Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM\/IL-6\/JAK-induced cancer cell plasticity","volume":"134","author":"Peyvandi","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2025.01.042_bb0240","doi-asserted-by":"crossref","first-page":"14979","DOI":"10.1038\/ncomms14979","article-title":"Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade","volume":"8","author":"Ouzounova","year":"2017","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2025.01.042_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083670","article-title":"TG1042 (Adenovirus-interferon-gamma) in primary cutaneous B-cell lymphomas: a phase II clinical trial","volume":"9","author":"Dreno","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jconrel.2025.01.042_bb0250","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1016\/j.biomaterials.2011.01.008","article-title":"Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided in vivo delivery of interferon gamma for cancer immunotherapy","volume":"32","author":"Mejias","year":"2011","journal-title":"Biomaterials"},{"issue":"9","key":"10.1016\/j.jconrel.2025.01.042_bb0255","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1021\/acs.molpharmaceut.8b00564","article-title":"Co-delivery of doxorubicin and interferon-gamma by thermosensitive nanoparticles for cancer immunochemotherapy","volume":"15","author":"Yin","year":"2018","journal-title":"Mol. Pharm."},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2025.01.042_bb0260","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1388-1981(00)00174-8","article-title":"Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects","volume":"1530","author":"Van Slooten","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2025.01.042_bb0265","doi-asserted-by":"crossref","first-page":"14023","DOI":"10.1038\/mtm.2014.23","article-title":"Prevention of adverse events of interferon gamma gene therapy by gene delivery of interferon gamma-heparin-binding domain fusion protein in mice","volume":"1","author":"Ando","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"10.1016\/j.jconrel.2025.01.042_bb0270","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1039\/C9BM00393B","article-title":"Chitosan\/poly(gamma-glutamic acid) nanoparticles incorporating IFN-gamma for immune response modulation in the context of colorectal cancer","volume":"7","author":"Castro","year":"2019","journal-title":"Biomater. Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:26:47Z","timestamp":1762259207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925000525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":54,"alternative-id":["S0168365925000525"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.042","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chitosan\/\u03b3-PGA nanoparticles and IFN-\u03b3 immunotherapy: A dual approach for triple-negative breast cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}